Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients

Código QR

Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients

Anna Dietrich-Muszalska,1 Joanna Kolodziejczyk-Czepas,2 Pawel Nowak2 1Medical University of Lodz, Department of Biological Psychiatry and Neurophysiology, Lodz, Poland; 2University of Lodz, Department of General Biochemistry, Lodz, PolandCorrespondence: Anna Dietrich-MuszalskaDepartment of Biologica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dietrich-Muszalska A, Kolodziejczyk-Czepas J, Nowak P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	schizophrenia antipsychotics f2-isoprostanes tac other oxidative markers Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c8b4166047394773a74242960b45cd9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
por: Xu H, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir S, et al.
Publicado: (2016)

Lipid peroxidation and antioxidants in hyperlipidemia and hypertension
por: MORIEL,PATRICIA, et al.
Publicado: (2000)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
por: Hýža M, et al.
Publicado: (2021)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
por: Suda A, et al.
Publicado: (2018)

Characterization of antipsychotic medications, amino acid signatures, and platelet-activating factor in first-episode psychosis
por: Bracha Erlanger Avigdor, et al.
Publicado: (2021)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Use of atypical antipsychotics in the elderly: a clinical review
por: Gareri P, et al.
Publicado: (2014)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
por: Li Y, et al.
Publicado: (2021)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Tzu-Pei Yeh, et al.
Publicado: (2021)

Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment
por: Moga S, et al.
Publicado: (2021)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
por: Lei Chen, et al.
Publicado: (2021)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Esquizofrenia y su asociación con enfermedades médicas crónicas
por: Orellana,Gricel, et al.
Publicado: (2017)

Drug Attitude, Insight, and Patient’s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey
por: Nagai N, et al.
Publicado: (2020)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang X, et al.
Publicado: (2019)

A systematic review of the effects of psychiatric medications on social cognition
por: Zoë Haime, et al.
Publicado: (2021)

Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
por: Huang YC, et al.
Publicado: (2018)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi T, et al.
Publicado: (2017)

Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia
por: Fan L, et al.
Publicado: (2021)

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
por: Takeshima M, et al.
Publicado: (2018)

Gender Differences in the First-Year Antipsychotic Treatment for Chinese First-Episode Schizophrenia
por: Pu C, et al.
Publicado: (2020)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi T, et al.
Publicado: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
por: Patrick Köck, et al.
Publicado: (2021)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Mitochondria: Aging, Metabolic Syndrome and Cardiovascular Diseases. Formation of a New Paradigm
por: A. V. Panov, et al.
Publicado: (2020)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic M, et al.
Publicado: (2018)

Minor Physical Anomalies Among Schizophrenic Patients as a Biomarker of Its Developmental Origin in Northwest Ethiopia
por: Tsehay B, et al.
Publicado: (2020)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

COMPARISON OF TWO WIDELY USED ATYPICAL ANTIPSYCHOTICS OLANZAPINE VERSUS RISPERIDONE IN TERMS OF METABOLIC OUTCOMES
por: Shiraz Hussain, et al.
Publicado: (2021)

Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia
por: Wang Y, et al.
Publicado: (2017)

Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database
por: Takekita Y, et al.
Publicado: (2020)